REC-4881 is under clinical development by Recursion Pharmaceuticals and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how REC-4881’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
REC-4881 overview
REC-4881 is under development for the treatment of familial adenomatous polyposis, solid tumor, colorectal cancer, hepatocellular carcinoma and ovarian cancer. The drug candidate is an orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity.
It was under development for the treatment of solid tumors (non-hematologic malignancy) and metastatic melanoma, hereditary cancer syndrome, solid tumors.
Recursion Pharmaceuticals overview
Recursion Pharmaceuticals (Recursion) is an artificial intelligence (AI)-driven biopharmaceutical company. It provides products that include a Robotics Platform, Recursion Operating System. Recursion has the pipeline disease model which includes Phase II Candidate: Cerebral Cavernous Malformation, Phase I Candidate: Neurofibromatosis Type 2, Phase I Candidate: Familial Adenomatous Polyposis, Phase I Candidate: GM2 Gangliosidosis. The company also offers target discovery and lead optimization services to its partner companies for furthering their clinical investigation. Recursion is headquartered in Salt Lake City, Utah, the US.
For a complete picture of REC-4881’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.